Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8432120 | 0.86 | HTT (0.48) | DDB1CRBNALDH1A1LMNAPOLB | |
| SCHEMBL16347174 | 0.83 | CETP (0.50) | ALDH1A1LMNAPOLBPKMMAPT | |
| SCHEMBL16345546 | 0.82 | CETP (0.51) | ALDH1A1LMNAPOLBPKMMAPT | |
| SCHEMBL16344798 | 0.82 | CETP (0.51) | ALDH1A1LMNAPOLBPKMMAPT | |
| SCHEMBL16345450 | 0.82 | CETP (0.51) | ALDH1A1LMNAPOLBPKMMAPT | |
| SCHEMBL16344589 | 0.81 | CETP (0.50) | ALDH1A1LMNAPOLBPKMMAPT | |
| SCHEMBL29346932 | 0.81 | DDB1 (0.46) | DDB1CRBNALDH1A1POLBMAPT | |
| SCHEMBL21915775 | 0.80 | DDB1 (0.50) | DDB1CRBNALDH1A1KMT2A | |
| SCHEMBL8395079 | 0.79 | DDB1 (0.49) | DDB1CRBNALDH1A1KMT2A | |
| SCHEMBL5902320 | 0.78 | ALDH1A1 (0.47) | DDB1CRBNALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0807627-B1 | Anilide compounds as ACAT inhibitors | KOWA CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6825223-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS; 2-SUBSTITUTED BENZIMIDAZOLE, BENZOXAZOLE, AND BENZOTHIAZOLES | KOWA COMPANY, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | SHIBUYA KIMIYUKI (JP) | 2002-03-28 | — | — | US | disclosed |
| US-6204278-B1 | Anilide compounds, including use thereof in ACAT inhibitition | KOWA COMPANY, LTD. (JP) | 2001-03-20 | — | — | US | disclosed |
| EP-0807627-A2 | Anilide compounds as ACAT inhibitors | Kowa Company Ltd. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | ACAT1, LCAT, SOAT1 | DDB1 4869/4885CRBN 3026/4885ALDH1A1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.